Table 1.
Prescribing Patterns, Durability, Regional 340b Pricing and Average Wholesale Price for 5 Common Regimens
| Regimen | N (%)a | Median (mos)[IQR] |
Regional 340b Priceb |
Average Wholesale Price |
|---|---|---|---|---|
| Emtricitabine, Tenofovir, Efavirenz | 277 (51) | 40.1 [12.6,77.5] | $726.26 | $2551.99 |
| Emtricitabine, Tenofovir, Rilpivirine | 30 (5) | 36.3 [17.4,*] | $917.50 | $2463.37 |
| Emtricitabine, Tenofovir, ritonavir/ Atazanavir | 48 (9) | 31.9 [16.6,58.6] | $1070.88 | $3369.22 |
| Emtricitabine, Tenofovir, Raltegravir | 75 (14) | 47.8 [22.6,*] | $1080.6 | $2985.24 |
| Emtricitabine, Tenofovir, ritonavir/Darunavir | 61(11) | 47.8 [25.5,*] | $1153.00 | $3358.29 |
a
Percentage refers to the percent of those receiving the specific treatment regimen out of 546 eligible patients
b
Regional 340b price is the actual acquisition cost charged to our clinic for the purchase of specific regimens
*
Note: The 75th percentile could not be estimated as the "event" percentage did not reach 75%
Definitions: ICER, Incremental Cost-Effectiveness Ratio, is calculated by comparing the difference in the cost divided by the difference in effect Durability defined as Median Durability from Kaplan-Meier Survival Curves